


	Research	Pre-clinical	Phase I	Phase II	Phase III	Registration	Commercial/ Phase IV
Life Cycle Management#							Immunoglobulins Haemophilia Specialty Products Influenza Vaccine
Market Development	PCC New Indications	C1-INH New Indications Fibrinogen New Formulations Haptoglobin/Hemopexin			HIZENTRA® CIDP PRIVIGEN® Japan Hizentra® IIM CSL842 C1-INH Transplant	PRIVIGEN® CIDP US KCENTRA® Japan CSL830 C1-INH subcut	VONCENTO® VWD EU RESPREEZA® EU/US
New Product Development	Next Gen Ig Formulations Rec Coagulation Factors P. gingivalis/POD OH-CRC Discovery Projects	CSL626 D'D3 LA rVIII CSL334 IL-13R* ASLAN CSL346 VEGFB	CSL689 rVIIa-FP Congen Def CSL640 rIX-FP subct CSL312 Anti-FXIIa CSL324 G-CSFR	CSL689 rVIIa-FP Inhibitors CAM3001 GM-CSFR – AZ* CSL362 IL-3R* AML Janssen CSL112 apo-AI		AFSTYLA® Europe AFLURIA® QIV 5-17 US, AUS	IDELVION® US, EU, Japan AFSTYLA® US AFLURIA® QIV 18+ US & AUS FLUAD® TIV 65+ US FLUCELVAX® QIV 4+ US

Core Capabilities: Immunoglobulins Haemophilia Specialty Products Breakthrough Medicines Vaccines & IP

*Partnered Projects



Expected Progress in next 12 Months



Global

Significant Target Launch Dates

2016	2017	2018	2019	2020	2021
PRIVIGEN® IsoLo	PRIVIGEN® CIDP US	HIZENTRA® CIDP US/EU	HIZENTRA® CIDP Japan PRIVIGEN® Japan PID/SID		
IDELVION® US IDELVION® EU IDELVION® Japan AFSTYLA® US	AFSTYLA® EU/Japan				CSL689 rVIIa-FP Prophylaxis CSL689 rVIIa-FP On Demand
	CSL830 HAEGARDA™ US KCENTRA® Japan	CSL830 EU			
AFLURIA® QIV 18+ US & AUS FLUAD® TIV 65+ US FLUCELVAX® QIV 4+ US	AFLURIA® QIV 6-17yr US	AFLURIA® QIV 6m-5yr US AFLURIA® QIV 6-17yr AUS FLUAD® QIV 6m-5yrs US	AFLURIA® QIV 6m-5yr AUS QIV EU		

Core Capabilities: Immunoglobulins Haemophilia Specialty Products Vaccines & IP

* Calendar Years